YD Bio Ltd (YDES) Financials

YD Bio Ltd (YDES) reported diluted earnings per share of -$0.12 for fiscal year 2025. This represents a -500.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

YD Bio Ltd (YDES) had EBITDA of -$5.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, YD Bio Ltd (YDES) had $6.0M in cash and equivalents against $7K in long-term debt.

YD Bio Ltd (YDES) had a gross margin of 28.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

YD Bio Ltd (YDES) recorded an outflow of $8.0M in free cash flow during fiscal year 2025. This represents a -519.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

YD Bio Ltd (YDES) recorded an outflow of $6.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

YD Bio Ltd (YDES) had $13.8M in total assets as of fiscal year 2025, including both current and long-term assets.

YD Bio Ltd (YDES) invested $1.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

YD Bio Ltd (YDES) invested $1.6M in research and development during fiscal year 2025.

YD Bio Ltd (YDES) had 71M shares outstanding as of fiscal year 2025.

YD Bio Ltd (YDES) had a current ratio of 5.88 as of fiscal year 2025, which is generally considered healthy.

YD Bio Ltd (YDES) had a return on assets of -60.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

YD Bio Ltd (YDES) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $276.3M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

YD Bio Ltd (YDES) trades at 463x sales, its market capitalization divided by revenue of $597K revenue, FY2025. The market capitalization is $276.3M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, YD Bio Ltd (YDES) held $6.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $6.6M over that year. Dividing the one by the other, the reported balance equals about 11 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

YD Bio Ltd (YDES) has negative shareholder equity of -$2.9M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

YD Bio Ltd (YDES) has an Altman Z-Score of 8.40, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

YD Bio Ltd (YDES) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

YD Bio Ltd (YDES) reported a net loss of $8.3M while operations used $6.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.